TG Therapeutics rises as European regulator backs multiple sclerosis drug

TG Therapeutics

31/03/2023 16:53

(Updates)
    ** Shares of drug developer TG Therapeutics Inc  TGTX.O 
rise 1.7% to $14.88 
    ** Co says the European health regulator's Committee for
Medicinal Products for Human Use (CHMP) recommended approval of
its drug candidate to treat relapsing forms of multiple
sclerosis in adults    
    ** The recommendation is based on data from two late-stage
trials showing significant reduction in relapse rate among
patients - TGTX
    ** Based on the CHMP recommendation, a decision by the
European Commission is expected in about two months - TGTX
    ** The drug ublituximab is approved in the U.S. for the same
indication and is sold under the brand name Briumvi -TGTX  
    ** Multiple sclerosis is a neurological disease in which the
immune system attacks the brain cells causing motor disabilities
    ** Stock rose ~26% so far this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))